Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

234
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
234
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

182
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
182
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

542
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
542
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

197
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
197
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

249
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
249
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

447
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
447
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Paediatrics
  9. Infant And Child Health
  11. Efficacy And Tolerability Of Selexipag In Pediatric Patients With Pulmonary Arterial Hypertension: An Updated Systematic Review And Meta-analysis.
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Paediatrics
  9. Infant And Child Health
  11. Efficacy And Tolerability Of Selexipag In Pediatric Patients With Pulmonary Arterial Hypertension: An Updated Systematic Review And Meta-analysis.

Related Experiment Video

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

14.5K

Efficacy and Tolerability of Selexipag in Pediatric Patients with Pulmonary Arterial Hypertension: An Updated Systematic Review and Meta-analysis.

Vasiliki Patsiou1,2,3, Triantafyllia Grantza1, Thomas Chrysochoidis-Trantas1

  • 1Pulmonary Hypertension and Congenital Heart Disease Unit, AHEPA University General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Pediatric Cardiology
|November 17, 2025

View abstract on PubMed

Summary
This summary is machine-generated.

Selexipag improved functional capacity in pediatric pulmonary arterial hypertension (PAH) patients, showing significant gains in the 6-minute walk distance. The drug was generally well-tolerated, though adverse events were noted in over 60% of participants.

Keywords:
EfficacyPediatricPharmacotherapyPulmonary hypertension

More Related Videos

Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension
09:23

Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension

Published on: February 11, 2017

17.3K
Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

687

Related Experiment Videos

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

14.5K
Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension
09:23

Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension

Published on: February 11, 2017

17.3K
Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

687

Area of Science:

  • Pediatric Cardiology
  • Pharmacology
  • Clinical Research

Background:

  • Evidence for selexipag in pediatric pulmonary arterial hypertension (PAH) is limited, stemming from small, diverse studies.
  • Pulmonary arterial hypertension (PAH) in children requires effective and safe treatment options.

Purpose of the Study:

  • To assess the efficacy and tolerability of selexipag in pediatric PAH patients through a meta-analysis.
  • To evaluate selexipag's impact on clinical outcomes and adverse events in children with PAH.

Main Methods:

  • A systematic literature search was performed across major databases (PubMed, Embase, Web of Science, Cochrane, Scopus) until April 2025.
  • Included studies involved pediatric patients (<18 years) diagnosed with PAH and treated with selexipag, reporting clinical outcomes.
Safety
Selexipag
Survival
Targeted-therapy
  • Pooled analyses of efficacy (6-minute walk distance, pulmonary vascular resistance index, mean pulmonary artery pressure, NT-proBNP) and safety outcomes were conducted.

    • Main Results:

    • Selexipag significantly improved 6-minute walk distance (SMD: -0.75; P=0.002) but did not significantly alter pulmonary vascular resistance index, mean pulmonary artery pressure (mPAP), or NT-proBNP.
    • Sensitivity analysis indicated a reduction in mPAP in PAH-only studies (SMD: -0.30; P=0.03).
    • Adverse events occurred in 62.8% of patients, mostly mild; functional improvement was greater in the add-on therapy group, which also had more adverse events.

    Conclusions:

    • Selexipag demonstrates efficacy in improving functional capacity and potentially mean pulmonary artery pressure in pediatric PAH patients.
    • The medication is generally well-tolerated, with most adverse events being mild.
    • Further prospective research is necessary to confirm the long-term benefits and optimal use of selexipag in pediatric PAH.